{"Title": ["Heska Corp. (HSKA) Shares Cross Above 200 DMA", "Heska Corporation (HSKA) Q1 2020 Earnings Call Transcript", "WHO Says There's No Evidence That Pets Can Pass Coronavirus to Humans", "Heska Corporation (HSKA) Q4 2019 Earnings Call Transcript", "You Love Your Dog More Than Humans -- And This Company's Reaping the Benefits", "We Love Our Pets, and IDEXX Knows It", "Heska Corporation (HSKA) Q3 2019 Earnings Call Transcript", "Heska Corporation (HSKA) Q2 2019 Earnings Call Transcript", "Heska Corp. (HSKA) Shares Cross Above 200 DMA", "Heska Corporation (HSKA) Q4 2018 Earnings Conference Call Transcript", "An ETF to Capitalize on the Booming Pet Industry", "Heska (HSKA) Surpasses Q3 Earnings Estimates", "Why We Believe Henry Schein's Upcoming Animal Health Spin-Off Will Unlock 30% To 50% Upside", "New Strong Sell Stocks for July 9th", "Why Heska (HSKA) Might Surprise This Earnings Season", "Validea Peter Lynch Strategy Daily Upgrade Report - 12/7/2017", "Add Up The Parts: VIOO Could Be Worth $161", "Heska Corporation (HSKA) Q4 2018 Earnings Conference Call Transcript", "An ETF to Capitalize on the Booming Pet Industry", "Heska (HSKA) Surpasses Q3 Earnings Estimates", "Why We Believe Henry Schein's Upcoming Animal Health Spin-Off Will Unlock 30% To 50% Upside", "New Strong Sell Stocks for July 9th", "Why Heska (HSKA) Might Surprise This Earnings Season", "Validea Peter Lynch Strategy Daily Upgrade Report - 12/7/2017", "Add Up The Parts: VIOO Could Be Worth $161", "Heska Corporation (HSKA) Q4 2018 Earnings Conference Call Transcript", "An ETF to Capitalize on the Booming Pet Industry", "Heska (HSKA) Surpasses Q3 Earnings Estimates", "Why We Believe Henry Schein's Upcoming Animal Health Spin-Off Will Unlock 30% To 50% Upside", "New Strong Sell Stocks for July 9th", "Why Heska (HSKA) Might Surprise This Earnings Season", "5 Efficient Stocks to Buy for a Healthy Portfolio", "Mariko Gordon Starts 5 New Positions in 3rd Quarter", "5 Top Efficient Stocks to Boost Your Portfolio", "Here's Why Heska Corporation Is Dropping Today", "CVS Health (CVS) Q1 Earnings Beat Estimates, Decrease Y/Y", "Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus", "Radius Health (RDUS) Posts Wider Q1 Loss, Tymlos Approved", "Hill-Rom (HRC) Beats Earnings & Revenue Estimates in Q2", "Sarepta (SRPT) Q1 Loss Narrows, Exondys 51 Sales Pick Up", "Why Heska (HSKA) Could Be Positioned for a Surge", "5 Top Efficient Stocks to Boost Your Portfolio", "Here's Why Heska Corporation Is Dropping Today", "CVS Health (CVS) Q1 Earnings Beat Estimates, Decrease Y/Y", "Exelixis (EXEL) Posts Earnings in Q1, Cabometyx in Focus", "Alkermes (ALKS) Q1 Loss Wider than Expected, Sales Miss", "The Medicines Company (MDCO) Q1 Loss Wider Than Expected", "Chemed's (CHE) Earnings and Revenues Beat Estimates in Q1", "AstraZeneca (AZN) Q1 Earnings Beat, Revenues Meet Estimates", "Alexion (ALXN) Tops Q1 Earnings, Revenues; Ups '17 View", "Zacks.com featured highlights: Heska, Zeltiq Aesthetics, YY, MaxLinear and Teradyne", "CytRx Gets Clarity from FDA for Aldoxorubicin NDA, Shares Up", "Ultragenyx's Hypophosphatemia Drug Succeeds in Phase III", "Arena Pharma (ARNA) Down After Underwritten Public Offering", "Create an Efficient Portfolio with 5 Top Stocks", "Bristol-Myers and Nordic Ink Biomarker Collaboration Deal", "Pacira Focuses on Lead Candidate Exparel's Label Expansion", "Bristol-Myers (BMY) Collaborates with Apexigen for Opdivo", "ANTH's (ANTH) Blisibimod Completes Dosing in Phase III Study", "Ohr Pharmaceutical Provides Update on Squalamine Study", "OncoMed Cancer Candidate Fails Trial, Bayer Opts Out of Deal", "Endo (ENDP) Reports Preliminary Results for First Quarter", "Ultragenyx's (RARE) XLH Drug Positive in Phase II Study", "Neurocrine's Stock Up, FDA Nod for Tardive Dyskinesia Drug", "Roche's Lung Cancer Drug Alecensa Meets Primary Endpoint", "Regeneron's Evinacumab Gets Breakthrough Therapy by FDA", "Bristol-Myers' (BMY) sBLA For Opdivo Accepted by the FDA", "Roche Announces Positive Data on Lung Cancer Drug Alecensa", "Valeant (VRX) Faces Pricing Issues, Generic Threats Loom", "Agenus (AGEN) Sharpens Focus on Drug Development Programs", "Amedisys (AMED) Poised on Strong Home Health, Risks Remain", "Gilead (GILD) HCV Drugs Gets FDA Nod for Label Expansion", "Celgene (CELG) Gets Paragraph IV Notice Letter for Pomalyst", "Bristol-Myers Announces Data on Immuno-oncology Drug Opdivo", "QIAGEN Releases Favorable GeneReader Results, Expands in NGS", "Jazz Pharma Completes NDA Filing for Leukemia Drug to FDA", "Zacks.com featured highlights: Heska, Quidel, Trinseo S.A., Advanced Energy Industries and Pioneer Natural Resources", "Galapagos Initiates 3 Phase II Studies for Filgotinib", "BioDelivery to Grant New Patents for its Marketed Drugs", "Today's Strong Buy Stocks at New Highs", "Bayer Announced Positive Data for Cancer Drug Copanlisib", "GlaxoSmithKline Initiates Phase III Study with Mepolizumab", "Spectrum (SPPI) Initiates Phase II Study for Cancer Candidate", "Bill Ackman Apologizes for Valeant Investment Error", "Acorda Presents Data for Parkinson's Candidate CVT-301", "Amgen's Leukemia Drug Accepted for Priority Review by FDA", "Roche's Rituxan Gets FDA Advisory Committee's Recommendation", "5 Stocks with Solid Efficiency Ratio to Buy in April", "Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y", "Regeneron & Sanofi's Atopic Dermatitis Drug Gets FDA Nod", "Roche's Ocrevus Wins FDA Approval for 2 Forms of Sclerosis", "Athersys (ATHX) Stock Rallies as William Blair Initiates Coverage", "Corcept (CORT) Strives to Commercialize Key Drug Korlym", "Tesaro Wins FDA Approval for Ovarian Cancer Drug Zejula", "Will Endo's Troubles Continue to Dent Performance in 2017?", "Vertex Combo Data on Kalydeco+VX-661 Positive in Phase III", "Orexigen Posts Wider-than-Expected Loss in Q4; Sales Up Y/Y", "Why Heska Corporation (HSKA) Could Be an Impressive Growth Stock", "Merrimack (MACK) Starts Enrollment in Solid Tumors Study", "Roche's Rituxan Gets 'Breakthrough Therapy' Designation by FDA", "Alexion (ALXN) Files for Soliris' Label Expansion in Japan", "Gemphire Therapeutics (GEMP) Catches Eye: Stock Gains 12%", "XBiotech (XBIT) Catches Eye: Stock Moves Up 11.6% in Session", "Novo Nordisk: Positive CHMP Nod for Tresiba Label Expansion", "AVEO (AVEO) Reports Narrower-than-Expected Loss in Q4", "Keryx's Auryxia Added to Largest Medicare Part D Plan", "Bristol-Myers Squibb and CytomX Therapeutics Extend Deal", "Valeant's (VRX) Glaucoma Candidate Gets PDUFA Date from FDA", "Mylan Receives Tentative Approval from FDA for HIV Therapy", "Zacks.com featured highlights: American Woodmark, Heska, OraSure Technologies, Pioneer Natural Resources and Advanced Energy Industries", "Alnylam's LDL-Lowering Drug Positive in Phase II Study", "Shire (SHPG) Rare Disease Drug Gets Fast Track Designation", "Alexion (ALXN) Licenses Artubus Technology for Rare Diseases", "Alkermes Starts Phase III Study to Treat Multiple Sclerosis", "Valeant (VRX) Shares up on ValueAct's 5.2% Stake Increase", "Catalyst (CPRX) Reports Narrower-than-Expected Loss in Q4", "Shire's (SHPG) Cinryze Label Expanded for Pediatric Use", "Endo's (ENDP) Opana ER's Risk Benefit Evaluated by FDA", "Infinity (INFI) Reports Narrower-than-Expected Loss in Q4", "Top 5 Efficient Stocks to Buy Right Now", "Alimera Sciences, Inc. (ALIM) Looks Good: Stock Up 12.8%", "Endocyte (ECYT) Reports Wider-than-Expected Loss in Q4", "Epizyme (EPZM) Reports Narrower Q4 Loss, Pipeline in Focus", "Agenus (AGEN) Reports Narrower-than-Expected Loss in Q4", "VIVUS (VVUS) Beats on Q4 Earnings, Revenues Increase Y/Y", "Sucampo (SCMP) Beats Q4 Earnings, 2017 View Reaffirmed", "Perrigo Launches First to Market OTC Equivalent of Rogaine", "Allergan (AGN) and Editas Tie Up to Treat Eye Diseases", "GlaxoSmithKline's Nucala Positive in Label Expansion Study", "Adaptimmune Therapeutics (ADAP) Jumps: Stock Rises 10.5%", "Nabriva Therapeutics (NBRV) Catches Eye: Stock Gains 9.8%", "Incyte Treats First Patient in Phase II GVHD Study on Jakafi", "Abbott Labs to Close St. Jude Acquisition Later this Week", "Immunomedics Completes Enrollment In Cancer Drug Study", "Cempra (CEMP) Gets CRL from FDA for Pneumonia Candidate", "Seattle Genetics (SGEN): FDA Lifts Hold on Trial of AML Drug", "GlaxoSmithKline's Nucala Positive in Label Expansion Study", "Achillion Receives $15M from J&J for HCV Study Enrolment", "Abbott to Sell 2 Medical Device Businesses for St. Jude Buyout", "McKesson (MCK) Closes Rexall Health Acquisition in Canada", "Amphastar Stock Down on CRL for Asthma Drug in the U.S.", "Shire Gets FDA Approval for Label Expansion of Adynovate", "Apricus Launches Vitaros in Lebanon for Erectile Dysfunction", "Corbus Concludes Phase II study of Cystic Fibrosis Candidate", "Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold", "Horizon's Rare Disease Drug Quinsair Launched in Canada", "Synergy Reports Positive Top-Line Phase III Data on IBS Drug", "Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy", "Aerie (AERI) Rhopressa Regulatory Application Delayed Again", "Celgene's Otezla Gains Positive Recommendation from NICE", "Roche (RHHBY) Hemophilia A Drug Positive in Phase III", "Neothetics (NEOT) Begins Phase II Study on Lead Candidate", "Seattle Genetics' Acute Myeloid Leukemia Drug on FDA Hold", "Horizon's Rare Disease Drug Quinsair Launched in Canada", "Synergy Reports Positive Top-Line Phase III Data on IBS Drug", "Ionis/Biogen Spinraza Approved For Spinal Muscular Atrophy", "Aerie (AERI) Rhopressa Regulatory Application Delayed Again", "Celgene's Otezla Gains Positive Recommendation from NICE", "Roche (RHHBY) Hemophilia A Drug Positive in Phase III", "Neothetics (NEOT) Begins Phase II Study on Lead Candidate", "Ionis Receives $5 Million Milestone from J&J Unit for GI Drug", "Bristol-Myers, Calithera Team Up for Opdivo/CB-839 Combo", "Incyte/Merus Ink Collaboration for Bispecific Antibodies", "Exelixis, Ipsen Amend Exclusive Agreement for Cabometyx", "Merrimack (MACK) Drops as Breast Cancer Drug Trial Stops", "Juno Gets Breakthrough Therapy Status for Lymphoma Drug", "ACADIA Phase II Alzheimer's Drug Hits Primary Endpoint", "Teva Settles Foreign Bribery Charges with U.S. Government", "Allergan to Buy LifeCell to Boost Regenerative Medicine Suite", "Pfizer (PFE) Nimenrix Vaccine's Label Expanded in the EU", "Amgen Files for Approval of Osteoporosis Drug in Japan", "AbbVie (ABBV) Submits NDA for Next-Gen HCV Combo in US", "Sarepta's (SRPT) Application for DMD Drug Accepted in the EU", "Ionis (IONS) Receives Milestone Payment from AstraZeneca", "AstraZeneca (AZN) Presents Tagrisso Data at Medical Meeting", "Juno Reports Positive Phase I Study Data on Lymphoma Drug", "AbbVie Crohn's Disease Drug Gets Orphan Drug Status in U.S.", "Achillion, J&J to Initiate Phase IIb Study on HCV Combo", "Ultragenyx (RARE) Reports Positive Phase II Study on UX007", "Time to Focus on Heska (HSKA) for Strong Earnings Growth Potential", "Valeant (VRX) Ups Sales Force to Support Xifaxan/Relistor", "Novartis Offers Positive Data on Breast Cancer Drug LEE011", "Amicus Provides Regulatory Update on Fabry Disease Drug", "Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth", "Glaxo (GSK) Files Regulatory Application for Shingrix in EU", "Merck's New Drugs, Cost Management to Fuel Growth in 2017", "OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S.", "Juno's ROCKET Study on Clinical Hold Again, Shares Down", "Is Heska (HSKA) Stock a Solid Choice Right Now?", "Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial", "Amicus Provides Regulatory Update on Fabry Disease Drug", "Mallinckrodt (MNK) Tops Q4 Earnings on Solid Sales Growth", "Glaxo (GSK) Files Regulatory Application for Shingrix in EU", "Merck's New Drugs, Cost Management to Fuel Growth in 2017", "OPKO Health (OPK) Launches Kidney Drug Rayaldee in U.S.", "Juno's ROCKET Study on Clinical Hold Again, Shares Down", "Is Heska (HSKA) Stock a Solid Choice Right Now?", "Jazz Completes Patient Enrollment in JZP-110 Narcolepsy Trial", "Agios Presents Data from Dose Expansion Study of AG-120", "Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017", "Earnings Estimates Moving Higher for Heska (HSKA); Time to Buy?", "ACADIA Starts Phase II Schizophrenia Study on Pimavanserin", "Lily's Jardiance Effective in Lowering Cardiovascular Death", "The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte", "Intrexon (XON) Reports In-Line Loss in Q3, Revenues Miss", "Allergan's Fibristal Approved in Canada for Label Expansion", "Agios Presents Data from Dose Expansion Study of AG-120", "Apricus Biosciences Aims to Resubmit Vitaros NDA in 2017", "Earnings Estimates Moving Higher for Heska (HSKA); Time to Buy?", "ACADIA Starts Phase II Schizophrenia Study on Pimavanserin", "Lily's Jardiance Effective in Lowering Cardiovascular Death", "The Zacks Analyst Blog Highlights: Enzo Biochem, Exelixis, Genmab A/S, Heska and Incyte", "Intrexon (XON) Reports In-Line Loss in Q3, Revenues Miss", "Allergan's Fibristal Approved in Canada for Label Expansion", "Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus", "Zacks.com featured highlights: Heska, Teradyne, Nxstage Medical, Unifi and Rollins", "Heska (HSKA) Shares March Higher, Can It Continue?", "No Clue of Upcoming Trends? Buy These Efficient Stocks", "Top Ranked Momentum Stocks to Buy for November 4th", "Myriad Genetics to Present myRisk Data at Seattle Conference", "Qiagen: Molecular Diagnostics & Expansion Plans on Track", "Sucampo (SCMP) Beats Q3 Earnings & Revenues, Guides Up", "Endure Market Volatility with These 5 Low Beta Stocks", "Masimo Amends Nellcor's Pulse Oximetry Royalty Agreement", "Myriad Genetics Adds Assurex Health, Grows in Neuroscience", "Illumina Keen on Genome Network Growth & Global Expansion", "Align Technology's Invisalign Dependence: Boon or Curse?", "FDA Approves Edwards Lifesciences' Intuity Elite Heart Valve", "Myriad Genetics: Q4 Hit by Low Test Revenues, Gross Margin", "Zacks.com featured highlights: Sanderson Farms, Children's Place, Heska, Carbonite and HomeStreet", "PharMerica (PMC) Q2 Earnings in Line, Revenues Beat", "Heska (HSKA) Shares March Higher, Can It Continue?", "BioTelemetry (BEAT) Q2 Earnings, Revenues Beat; View Up", "Arena's (ARNA) Q2 Loss Narrower, Revenues Increase Y/Y", "Kite Pharma (KITE) Q2 Loss Wider but Focus is on KTE-C19", "Strength Seen in Heska (HSKA): Stock Jumps 5.7% in Session", "Myriad Genetics myChoice Cancer Test Findings Encourage", "MEDNAX (MD) Acquires Anesthesiology Practice in Nevada", "Heska (HSKA) Sees Hammer Chart Pattern: Time to Buy?", "New Strong Buy Stocks for June 2nd", "Galena Biopharma (GALE) in Focus: Stock Moves Up 19.3%", "Kite Pharma (KITE) Posts Narrower-than-Expected Loss in Q1", "Arena's (ARNA) Q1 Loss Narrower but Revenues Fall Short", "Juno (JUNO) Posts Wider Loss in Q1, Focus on Pipeline", "New Strong Buy Stocks for May 5th", "Dodge Market Volatility with These 5 Low-Beta Stocks", "7 A-Rated Small-Cap Stocks to Line Your Pockets", "OncoMed (OMED) Looks Good: Stock Moves 6.1% Higher", "Can the Rally in Heska (HSKA) Shares Continue?", "5 Best-Performing Russell 2000 Stocks of 2015", "Heska (HSKA) Looks Good: Stock Adds 5% in Session", "Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations", "Should You Dump Cardiovascular Systems (CSII) Now?", "Mid-Afternoon Market Update: Stratasys Rises On Upbeat Q4 Results; Ciena Shares Slide", "7 A-Rated Small-Cap Stocks to Line Your Pockets", "OncoMed (OMED) Looks Good: Stock Moves 6.1% Higher", "Can the Rally in Heska (HSKA) Shares Continue?", "5 Best-Performing Russell 2000 Stocks of 2015", "Heska (HSKA) Looks Good: Stock Adds 5% in Session", "Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations", "Should You Dump Cardiovascular Systems (CSII) Now?", "Mid-Afternoon Market Update: Stratasys Rises On Upbeat Q4 Results; Ciena Shares Slide", "7 A-Rated Small-Cap Stocks to Line Your Pockets", "OncoMed (OMED) Looks Good: Stock Moves 6.1% Higher", "Can the Rally in Heska (HSKA) Shares Continue?", "5 Best-Performing Russell 2000 Stocks of 2015", "Heska (HSKA) Looks Good: Stock Adds 5% in Session", "Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations", "Should You Dump Cardiovascular Systems (CSII) Now?", "Mid-Afternoon Market Update: Stratasys Rises On Upbeat Q4 Results; Ciena Shares Slide", "7 A-Rated Small-Cap Stocks to Line Your Pockets", "OncoMed (OMED) Looks Good: Stock Moves 6.1% Higher", "Can the Rally in Heska (HSKA) Shares Continue?", "5 Best-Performing Russell 2000 Stocks of 2015", "Heska (HSKA) Looks Good: Stock Adds 5% in Session", "Mid-Morning Market Update: Markets Edge Lower; Cal-Maine Misses Q2 Expectations", "Should You Dump Cardiovascular Systems (CSII) Now?", "Mid-Afternoon Market Update: Stratasys Rises On Upbeat Q4 Results; Ciena Shares Slide", "Should Heska Corporation (HSKA) Be On Your Radar Now?", "Vanda Pharmaceuticals (VNDA) Jumps: Stock Rises 7.9%", "Should You Retain Integra LifeSciences (IART) in Your Portfolio?", "Bluebird Bio Crashes After Clinical Trial Update", "Should You Dump Illumina (ILMN) from Your Portfolio Now?", "Repros Therapeutics (RPRX) Looks Good: Stock Soars 45.1%", "Can Heska (HSKA) Stock Continue to Grow Earnings?", "Myriad Genetics: Test Expansion Strong, Currency Woes Linger", "Strength Seen in Heska (HSKA): Stock Moves 11.5% Higher", "Will Heska (HSKA) Continue to Surge Higher? - Tale of the Tape", "Why Heska Corporation (HSKA) Could Be an Impressive Growth Stock - Tale of the Tape", "Integra Tops Earnings & Revenues, Guides Low on Spine Sale - Analyst Blog", "Qiagen (QGEN) Beats Q2 Earnings, Revenues; Keeps '15 View - Analyst Blog", "Repros Therapeutics (RPRX) Worth Watching: Stock Up 17% - Tale of the Tape", "Rexahn Pharmaceuticals (RNN) Jumps: Stock Gains 10.2% - Tale of the Tape", "Can The Uptrend Continue for Heska (HSKA)? - Tale of the Tape", "Qiagen's Molecular Diagnostics, Global Market Show Strength - Analyst Blog", "Dynavax (DVAX) Jumps: Stock Moves 6.7% Higher - Tale of the Tape", "Alder Biopharmaceuticals (ALDR) in Focus: Stock Up 5.2% - Tale of the Tape", "Dendreon (DNDN) in Focus: Stock Up 9.4% - Tale of the Tape", "Is Illumina (ILMN) a Buy on Solid Q2, Strategic Road Map? - Analyst Blog", "Cytokinetics (CYTK) Looks Strong: Stock Gains 17.2% - Tale of the Tape", "Discovery Laboratories (DSCO) Worth Watching: Stock Up 6.9% - Tale of the Tape", "Myriad Genetics Poised on Strong myRisk, Overseas Results - Analyst Blog", "Genomic Health Remains Neutral - Analyst Blog", "Synthetic Biologics (SYN) in Focus: Stock Surges 18.1% - Tale of the Tape", "Synergy Pharmaceuticals Catches Eyes: Stock Jumps 8.6% - Tale of the Tape", "Jazz Pharmaceuticals plc (JAZZ) Catches Eye: Stock Rises 8% - Tale of the Tape", "Myriad Maintained at Neutral - Analyst Blog", "Affymetrix Reaches New 52-Week High - Analyst Blog", "Ariad Pharmaceuticals (ARIA) Worth Watching: Stock Surges 19.7% - Tale of the Tape", "Edwards Lifesciences Lifted to Hold - Analyst Blog", "MYGN Announces Results of HRD Test - Analyst Blog", "IART Publishes Positive Study Results - Analyst Blog", "MYGN Unveils Positive Study Results - Analyst Blog", "DaVita HealthCare Partners (DVA) Catches Eye: Stock Rises 6.7% - Tale of the Tape", "Verastem (VSTM) in Focus: Stock Rises by 7.3% - Tale of the Tape", "MYGN Unveils Prolaris Study Results - Analyst Blog", "Sangamo Biosciences (SGMO) in Focus: Stock Rises 5.8% - Tale of the Tape", "Agenus (AGEN) Soars: Stock Adds 12.7% in Session - Tale of the Tape", "MYGN Announces Results of HRD Test - Analyst Blog", "IART Publishes Positive Study Results - Analyst Blog", "MYGN Unveils Positive Study Results - Analyst Blog", "Oncothyreon Inc. (ONTY) in Focus: Stock Up 5.2% - Tale of the Tape", "Transition Therapeutics (TTHI) Jumps: Stock Adds 7.0% in Session - Tale of the Tape", "Chelsea Therapeutics (CHTP) Looks Good: Stock Moves 8.9% Higher - Tale of the Tape", "Affymetrix Remains Outperform - Analyst Blog", "Athersys (ATHX) Catches Eye: Stock Jumps 5.5% - Tale of the Tape", "Curis, Inc. (CRIS) Soars: Stock Adds 11.7% in Session - Tale of the Tape", "DaVita HealthCare Partners (DVA) Shows Strength: Stock Rises 8.9% - Tale of the Tape", "GHDX Partners Almac for Cancer Test - Analyst Blog", "Dynavax Technologies (DVAX) Catches Eye: Stock Rises 5.2% - Tale of the Tape", "Vanda Pharmaceuticals, Inc. (VNDA) Grabs Attention: Stock Shoots 95.9% - Tale of the Tape", "Arena Pharmaceuticals (ARNA) Worth a Look: Stock Surges 10.6% - Tale of the Tape", "Athersys (ATHX) Jumps: Stock Rises by 9.2% - Tale of the Tape"], "Elapsed Time": ["MAY 8, 2020", "MAY 8, 2020", "MAR 13, 2020", "FEB 25, 2020", "NOV 21, 2019", "NOV 12, 2019", "NOV 5, 2019", "AUG 6, 2019", "MAY 8, 2020", "FEB 26, 2019", "JAN 8, 2019", "NOV 6, 2018", "SEP 26, 2018", "JUL 9, 2018", "MAY 3, 2018", "DEC 7, 2017", "AUG 6, 2019", "FEB 26, 2019", "JAN 8, 2019", "NOV 6, 2018", "SEP 26, 2018", "JUL 9, 2018", "MAY 3, 2018", "DEC 7, 2017", "AUG 6, 2019", "FEB 26, 2019", "JAN 8, 2019", "NOV 6, 2018", "SEP 26, 2018", "JUL 9, 2018", "MAY 3, 2018", "AUG 25, 2017", "NOV 21, 2017", "MAY 4, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 1, 2017", "APR 28, 2017", "JUN 2, 2017", "MAY 4, 2017", "MAY 2, 2017", "MAY 2, 2017", "MAY 2, 2017", "APR 28, 2017", "APR 27, 2017", "APR 27, 2017", "APR 28, 2017", "APR 27, 2017", "APR 20, 2017", "APR 20, 2017", "APR 19, 2017", "APR 19, 2017", "APR 19, 2017", "APR 18, 2017", "APR 12, 2017", "APR 12, 2017", "APR 11, 2017", "APR 11, 2017", "APR 11, 2017", "APR 11, 2017", "APR 10, 2017", "APR 13, 2017", "APR 10, 2017", "APR 7, 2017", "APR 6, 2017", "APR 5, 2017", "APR 5, 2017", "APR 5, 2017", "APR 5, 2017", "APR 10, 2017", "APR 5, 2017", "APR 4, 2017", "APR 4, 2017", "APR 4, 2017", "APR 4, 2017", "APR 4, 2017", "APR 3, 2017", "APR 5, 2017", "APR 3, 2017", "APR 3, 2017", "MAR 31, 2017", "MAR 30, 2017", "MAR 30, 2017", "MAR 30, 2017", "MAR 30, 2017", "APR 3, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 28, 2017", "MAR 28, 2017", "MAR 29, 2017", "MAR 29, 2017", "MAR 27, 2017", "MAR 24, 2017", "MAR 24, 2017", "MAR 23, 2017", "MAR 23, 2017", "MAR 23, 2017", "MAR 28, 2017", "MAR 23, 2017", "MAR 22, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 21, 2017", "MAR 20, 2017", "MAR 20, 2017", "MAR 23, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 17, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 16, 2017", "MAR 15, 2017", "MAR 17, 2017", "MAR 14, 2017", "MAR 14, 2017", "MAR 10, 2017", "MAR 10, 2017", "MAR 9, 2017", "MAR 9, 2017", "MAR 9, 2017", "MAR 15, 2017", "MAR 7, 2017", "MAR 6, 2017", "MAR 3, 2017", "JAN 2, 2017", "JAN 2, 2017", "DEC 30, 2016", "DEC 30, 2016", "MAR 8, 2017", "DEC 29, 2016", "DEC 29, 2016", "DEC 29, 2016", "DEC 29, 2016", "DEC 28, 2016", "DEC 28, 2016", "DEC 28, 2016", "DEC 30, 2016", "DEC 28, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 23, 2016", "DEC 23, 2016", "DEC 28, 2016", "DEC 28, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 27, 2016", "DEC 23, 2016", "DEC 23, 2016", "DEC 28, 2016", "DEC 23, 2016", "DEC 22, 2016", "DEC 22, 2016", "DEC 22, 2016", "DEC 22, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 23, 2016", "DEC 21, 2016", "DEC 21, 2016", "DEC 20, 2016", "DEC 20, 2016", "DEC 20, 2016", "DEC 19, 2016", "DEC 7, 2016", "DEC 6, 2016", "DEC 1, 2016", "DEC 1, 2016", "DEC 1, 2016", "NOV 30, 2016", "NOV 30, 2016", "DEC 12, 2016", "NOV 29, 2016", "NOV 29, 2016", "NOV 28, 2016", "NOV 25, 2016", "NOV 25, 2016", "NOV 24, 2016", "NOV 23, 2016", "NOV 29, 2016", "NOV 29, 2016", "NOV 29, 2016", "NOV 28, 2016", "NOV 25, 2016", "NOV 25, 2016", "NOV 24, 2016", "NOV 23, 2016", "NOV 29, 2016", "NOV 21, 2016", "NOV 21, 2016", "NOV 17, 2016", "NOV 16, 2016", "NOV 14, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 22, 2016", "NOV 21, 2016", "NOV 21, 2016", "NOV 17, 2016", "NOV 16, 2016", "NOV 14, 2016", "NOV 11, 2016", "NOV 11, 2016", "NOV 22, 2016", "NOV 10, 2016", "NOV 9, 2016", "NOV 8, 2016", "NOV 8, 2016", "NOV 4, 2016", "SEP 28, 2016", "SEP 16, 2016", "NOV 10, 2016", "SEP 8, 2016", "SEP 6, 2016", "SEP 6, 2016", "AUG 26, 2016", "AUG 17, 2016", "AUG 17, 2016", "AUG 16, 2016", "SEP 9, 2016", "AUG 11, 2016", "AUG 10, 2016", "AUG 9, 2016", "AUG 9, 2016", "AUG 9, 2016", "JUL 11, 2016", "JUL 1, 2016", "AUG 15, 2016", "JUN 15, 2016", "JUN 2, 2016", "JUN 2, 2016", "MAY 10, 2016", "MAY 10, 2016", "MAY 10, 2016", "MAY 5, 2016", "MAY 17, 2016", "JAN 11, 2016", "JAN 6, 2016", "DEC 30, 2015", "DEC 29, 2015", "DEC 28, 2015", "DEC 24, 2015", "DEC 23, 2015", "MAR 3, 2016", "JAN 11, 2016", "JAN 6, 2016", "DEC 30, 2015", "DEC 29, 2015", "DEC 28, 2015", "DEC 24, 2015", "DEC 23, 2015", "MAR 3, 2016", "JAN 11, 2016", "JAN 6, 2016", "DEC 30, 2015", "DEC 29, 2015", "DEC 28, 2015", "DEC 24, 2015", "DEC 23, 2015", "MAR 3, 2016", "JAN 11, 2016", "JAN 6, 2016", "DEC 30, 2015", "DEC 29, 2015", "DEC 28, 2015", "DEC 24, 2015", "DEC 23, 2015", "MAR 3, 2016", "DEC 11, 2015", "DEC 10, 2015", "DEC 9, 2015", "DEC 7, 2015", "DEC 7, 2015", "NOV 30, 2015", "NOV 18, 2015", "DEC 22, 2015", "NOV 12, 2015", "AUG 5, 2015", "AUG 4, 2015", "AUG 3, 2015", "JUL 31, 2015", "SEP 29, 2014", "SEP 26, 2014", "DEC 26, 2014", "SEP 26, 2014", "SEP 22, 2014", "SEP 18, 2014", "SEP 16, 2014", "SEP 16, 2014", "SEP 11, 2014", "AUG 21, 2014", "SEP 26, 2014", "DEC 27, 2013", "DEC 24, 2013", "DEC 24, 2013", "DEC 23, 2013", "DEC 23, 2013", "DEC 23, 2013", "DEC 19, 2013", "DEC 31, 2013", "DEC 17, 2013", "DEC 16, 2013", "DEC 13, 2013", "DEC 10, 2013", "DEC 6, 2013", "DEC 5, 2013", "DEC 4, 2013", "DEC 17, 2013", "DEC 17, 2013", "DEC 16, 2013", "DEC 13, 2013", "DEC 2, 2013", "NOV 27, 2013", "NOV 27, 2013", "DEC 4, 2013", "NOV 26, 2013", "NOV 26, 2013", "NOV 26, 2013", "NOV 26, 2013", "NOV 25, 2013", "NOV 13, 2013", "NOV 12, 2013", "NOV 22, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/heska-corp.-hska-shares-cross-above-200-dma-2020-05-08", "https://www.nasdaq.com/articles/heska-corporation-hska-q1-2020-earnings-call-transcript-2020-05-08", "https://www.nasdaq.com/articles/who-says-theres-no-evidence-that-pets-can-pass-coronavirus-to-humans-2020-03-13", "https://www.nasdaq.com/articles/heska-corporation-hska-q4-2019-earnings-call-transcript-2020-02-25", "https://www.nasdaq.com/articles/you-love-your-dog-more-than-humans-and-this-companys-reaping-the-benefits-2019-11-21", "https://www.nasdaq.com/articles/we-love-our-pets-and-idexx-knows-it-2019-11-12", "https://www.nasdaq.com/articles/heska-corporation-hska-q3-2019-earnings-call-transcript-2019-11-05", "https://www.nasdaq.com/articles/heska-corporation-hska-q2-2019-earnings-call-transcript-2019-08-07", "https://www.nasdaq.com/articles/heska-corp.-hska-shares-cross-above-200-dma-2020-05-08", "https://www.nasdaq.com/articles/heska-corporation-hska-q4-2018-earnings-conference-call-transcript-2019-02-26", "https://www.nasdaq.com/articles/etf-capitalize-booming-pet-industry-2019-01-08", "https://www.nasdaq.com/articles/heska-hska-surpasses-q3-earnings-estimates-2018-11-06", "https://www.nasdaq.com/articles/why-we-believe-henry-scheins-upcoming-animal-health-spin-will-unlock-30-50-upside-2018-09", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-july-9th-2018-07-09", "https://www.nasdaq.com/articles/why-heska-hska-might-surprise-this-earnings-season-2018-05-03", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-1272017-2017-12-07", "https://www.nasdaq.com/articles/add-up-the-parts%3A-vioo-could-be-worth-%24161-2019-08-06", "https://www.nasdaq.com/articles/heska-corporation-hska-q4-2018-earnings-conference-call-transcript-2019-02-26", "https://www.nasdaq.com/articles/etf-capitalize-booming-pet-industry-2019-01-08", "https://www.nasdaq.com/articles/heska-hska-surpasses-q3-earnings-estimates-2018-11-06", "https://www.nasdaq.com/articles/why-we-believe-henry-scheins-upcoming-animal-health-spin-will-unlock-30-50-upside-2018-09", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-july-9th-2018-07-09", "https://www.nasdaq.com/articles/why-heska-hska-might-surprise-this-earnings-season-2018-05-03", "https://www.nasdaq.com/articles/validea-peter-lynch-strategy-daily-upgrade-report-1272017-2017-12-07", "https://www.nasdaq.com/articles/add-up-the-parts%3A-vioo-could-be-worth-%24161-2019-08-06", "https://www.nasdaq.com/articles/heska-corporation-hska-q4-2018-earnings-conference-call-transcript-2019-02-26", "https://www.nasdaq.com/articles/etf-capitalize-booming-pet-industry-2019-01-08", "https://www.nasdaq.com/articles/heska-hska-surpasses-q3-earnings-estimates-2018-11-06", "https://www.nasdaq.com/articles/why-we-believe-henry-scheins-upcoming-animal-health-spin-will-unlock-30-50-upside-2018-09", "https://www.nasdaq.com/articles/new-strong-sell-stocks-for-july-9th-2018-07-09", "https://www.nasdaq.com/articles/zacks.com-featured-highlights-sanderson-farm-heska-corp-vanda-pharmaceuticals-lantheus-and", "https://www.nasdaq.com/articles/5-efficient-stocks-buy-healthy-portfolio-2017-08-25", "https://www.nasdaq.com/articles/mariko-gordon-starts-5-new-positions-3rd-quarter-2017-11-21", "https://www.nasdaq.com/articles/5-top-efficient-stocks-boost-your-portfolio-2017-05-04", "https://www.nasdaq.com/articles/heres-why-heska-corporation-dropping-today-2017-05-02", "https://www.nasdaq.com/articles/cvs-health-cvs-q1-earnings-beat-estimates-decrease-y-y-2017-05-02", "https://www.nasdaq.com/articles/exelixis-exel-posts-earnings-in-q1-cabometyx-in-focus-2017-05-02", "https://www.nasdaq.com/articles/radius-health-rdus-posts-wider-q1-loss-tymlos-approved-2017-05-02", "https://www.nasdaq.com/articles/hill-rom-hrc-beats-earnings-revenue-estimates-in-q2-2017-05-01", "https://www.nasdaq.com/articles/sarepta-srpt-q1-loss-narrows-exondys-51-sales-pick-up-2017-04-28", "https://www.nasdaq.com/articles/why-heska-hska-could-be-positioned-for-a-surge-2017-06-02", "https://www.nasdaq.com/articles/5-top-efficient-stocks-boost-your-portfolio-2017-05-04", "https://www.nasdaq.com/articles/heres-why-heska-corporation-dropping-today-2017-05-02", "https://www.nasdaq.com/articles/cvs-health-cvs-q1-earnings-beat-estimates-decrease-y-y-2017-05-02", "https://www.nasdaq.com/articles/sanofi-sny-q1-earnings-top-sales-rise-y-y-shares-up-2017-04-28", "https://www.nasdaq.com/articles/alkermes-alks-q1-loss-wider-than-expected-sales-miss-2017-04-28", "https://www.nasdaq.com/articles/the-medicines-company-mdco-q1-loss-wider-than-expected-2017-04-27", "https://www.nasdaq.com/articles/chemeds-che-earnings-and-revenues-beat-estimates-in-q1-2017-04-27", "https://www.nasdaq.com/articles/astrazeneca-azn-q1-earnings-beat-revenues-meet-estimates-2017-04-28", "https://www.nasdaq.com/articles/alexion-alxn-tops-q1-earnings-revenues-ups-17-view-2017-04-27", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-heska-zeltiq-aesthetics-yy-maxlinear-and-teradyne-2017-04", "https://www.nasdaq.com/articles/cytrx-gets-clarity-from-fda-for-aldoxorubicin-nda-shares-up-2017-04-20", "https://www.nasdaq.com/articles/ultragenyxs-hypophosphatemia-drug-succeeds-in-phase-iii-2017-04-19", "https://www.nasdaq.com/articles/arena-pharma-arna-down-after-underwritten-public-offering-2017-04-19", "https://www.nasdaq.com/articles/illumina-ilmn-launches-veriseq-nipt-solution-in-europe-2017-04-13", "https://www.nasdaq.com/articles/bristol-myers-and-nordic-ink-biomarker-collaboration-deal-2017-04-18", "https://www.nasdaq.com/articles/pacira-focuses-on-lead-candidate-exparels-label-expansion-2017-04-12", "https://www.nasdaq.com/articles/bristol-myers-bmy-collaborates-with-apexigen-for-opdivo-2017-04-12", "https://www.nasdaq.com/articles/anths-anth-blisibimod-completes-dosing-in-phase-iii-study-2017-04-11", "https://www.nasdaq.com/articles/ohr-pharmaceutical-provides-update-on-squalamine-study-2017-04-11", "https://www.nasdaq.com/articles/oncomed-cancer-candidate-fails-trial-bayer-opts-out-of-deal-2017-04-11", "https://www.nasdaq.com/articles/endo-endp-reports-preliminary-results-for-first-quarter-2017-04-11", "https://www.nasdaq.com/articles/ultragenyxs-rare-xlh-drug-positive-in-phase-ii-study-2017-04-10", "https://www.nasdaq.com/articles/neurocrines-stock-up-fda-nod-for-tardive-dyskinesia-drug-2017-04-13", "https://www.nasdaq.com/articles/roches-lung-cancer-drug-alecensa-meets-primary-endpoint-2017-04-10", "https://www.nasdaq.com/articles/regenerons-evinacumab-gets-breakthrough-therapy-by-fda-2017-04-07", "https://www.nasdaq.com/articles/bristol-myers-bmy-sbla-for-opdivo-accepted-by-the-fda-2017-04-06", "https://www.nasdaq.com/articles/roche-announces-positive-data-on-lung-cancer-drug-alecensa-2017-04-05", "https://www.nasdaq.com/articles/valeant-vrx-faces-pricing-issues-generic-threats-loom-2017-04-05", "https://www.nasdaq.com/articles/agenus-agen-sharpens-focus-on-drug-development-programs-2017-04-05", "https://www.nasdaq.com/articles/amedisys-amed-poised-on-strong-home-health-risks-remain-2017-04-05", "https://www.nasdaq.com/articles/gilead-gild-hcv-drugs-gets-fda-nod-for-label-expansion-2017-04-10", "https://www.nasdaq.com/articles/celgene-celg-gets-paragraph-iv-notice-letter-for-pomalyst-2017-04-05", "https://www.nasdaq.com/articles/bristol-myers-announces-data-on-immuno-oncology-drug-opdivo-2017-04-04", "https://www.nasdaq.com/articles/qiagen-releases-favorable-genereader-results-expands-in-ngs-2017-04-04", "https://www.nasdaq.com/articles/jazz-pharma-completes-nda-filing-for-leukemia-drug-to-fda-2017-04-04", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-heska-quidel-trinseo-s.a.-advanced-energy-industries-and", "https://www.nasdaq.com/articles/galapagos-initiates-3-phase-ii-studies-for-filgotinib-2017-04-04", "https://www.nasdaq.com/articles/biodelivery-to-grant-new-patents-for-its-marketed-drugs-2017-04-03", "https://www.nasdaq.com/articles/todays-strong-buy-stocks-new-highs-2017-04-05", "https://www.nasdaq.com/articles/bayer-announced-positive-data-for-cancer-drug-copanlisib-2017-04-03", "https://www.nasdaq.com/articles/glaxosmithkline-initiates-phase-iii-study-with-mepolizumab-2017-04-03", "https://www.nasdaq.com/articles/spectrum-sppi-initiates-phase-ii-study-for-cancer-candidate-2017-03-31", "https://www.nasdaq.com/articles/bill-ackman-apologizes-for-valeant-investment-error-2017-03-30", "https://www.nasdaq.com/articles/acorda-presents-data-for-parkinsons-candidate-cvt-301-2017-03-30", "https://www.nasdaq.com/articles/amgens-leukemia-drug-accepted-for-priority-review-by-fda-2017-03-30", "https://www.nasdaq.com/articles/roches-rituxan-gets-fda-advisory-committees-recommendation-2017-03-30", "https://www.nasdaq.com/articles/5-stocks-solid-efficiency-ratio-buy-april-2017-04-03", "https://www.nasdaq.com/articles/orexigen-posts-wider-than-expected-loss-in-q4-sales-up-y-y-2017-03-29", "https://www.nasdaq.com/articles/regeneron-sanofis-atopic-dermatitis-drug-gets-fda-nod-2017-03-29", "https://www.nasdaq.com/articles/roches-ocrevus-wins-fda-approval-for-2-forms-of-sclerosis-2017-03-29", "https://www.nasdaq.com/articles/athersys-athx-stock-rallies-as-william-blair-initiates-coverage-2017-03-29", "https://www.nasdaq.com/articles/corcept-cort-strives-to-commercialize-key-drug-korlym-2017-03-29", "https://www.nasdaq.com/articles/tesaro-wins-fda-approval-for-ovarian-cancer-drug-zejula-2017-03-28", "https://www.nasdaq.com/articles/will-endos-troubles-continue-to-dent-performance-in-2017-2017-03-28", "https://www.nasdaq.com/articles/vertex-combo-data-on-kalydecovx-661-positive-in-phase-iii-2017-03-29", "https://www.nasdaq.com/articles/bristol-myers-bmy-opdivo-gets-positive-chmp-opinion-2017-03-28", "https://www.nasdaq.com/articles/why-heska-corporation-hska-could-be-an-impressive-growth-stock-2017-03-27", "https://www.nasdaq.com/articles/merrimack-mack-starts-enrollment-in-solid-tumors-study-2017-03-24", "https://www.nasdaq.com/articles/roches-rituxan-gets-breakthrough-therapy-designation-by-fda-2017-03-24", "https://www.nasdaq.com/articles/alexion-alxn-files-for-soliris-label-expansion-in-japan-2017-03-23", "https://www.nasdaq.com/articles/gemphire-therapeutics-gemp-catches-eye-stock-gains-12-2017-03-23", "https://www.nasdaq.com/articles/xbiotech-xbit-catches-eye%3A-stock-moves-up-11.6-in-session-2017-03-23", "https://www.nasdaq.com/articles/novo-nordisk%3A-positive-chmp-nod-for-tresiba-label-expansion-2017-03-28", "https://www.nasdaq.com/articles/aveo-aveo-reports-narrower-than-expected-loss-in-q4-2017-03-23", "https://www.nasdaq.com/articles/keryxs-auryxia-added-to-largest-medicare-part-d-plan-2017-03-22", "https://www.nasdaq.com/articles/bristol-myers-squibb-and-cytomx-therapeutics-extend-deal-2017-03-21", "https://www.nasdaq.com/articles/valeants-vrx-glaucoma-candidate-gets-pdufa-date-from-fda-2017-03-21", "https://www.nasdaq.com/articles/mylan-receives-tentative-approval-from-fda-for-hiv-therapy-2017-03-21", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-american-woodmark-heska-orasure-technologies-pioneer", "https://www.nasdaq.com/articles/alnylams-ldl-lowering-drug-positive-in-phase-ii-study-2017-03-20", "https://www.nasdaq.com/articles/shire-shpg-rare-disease-drug-gets-fast-track-designation-2017-03-23", "https://www.nasdaq.com/articles/alexion-alxn-licenses-artubus-technology-for-rare-diseases-2017-03-17", "https://www.nasdaq.com/articles/alkermes-starts-phase-iii-study-to-treat-multiple-sclerosis-2017-03-17", "https://www.nasdaq.com/articles/valeant-vrx-shares-up-on-valueacts-5.2-stake-increase-2017-03-17", "https://www.nasdaq.com/articles/catalyst-cprx-reports-narrower-than-expected-loss-in-q4-2017-03-16", "https://www.nasdaq.com/articles/shires-shpg-cinryze-label-expanded-for-pediatric-use-2017-03-16", "https://www.nasdaq.com/articles/endos-endp-opana-ers-risk-benefit-evaluated-by-fda-2017-03-16", "https://www.nasdaq.com/articles/infinity-infi-reports-narrower-than-expected-loss-in-q4-2017-03-15", "https://www.nasdaq.com/articles/top-5-efficient-stocks-buy-right-now-2017-03-17", "https://www.nasdaq.com/articles/alimera-sciences-inc.-alim-looks-good%3A-stock-up-12.8-2017-03-14", "https://www.nasdaq.com/articles/endocyte-ecyt-reports-wider-than-expected-loss-in-q4-2017-03-14", "https://www.nasdaq.com/articles/epizyme-epzm-reports-narrower-q4-loss-pipeline-in-focus-2017-03-10", "https://www.nasdaq.com/articles/agenus-agen-reports-narrower-than-expected-loss-in-q4-2017-03-10", "https://www.nasdaq.com/articles/vivus-vvus-beats-on-q4-earnings-revenues-increase-y-y-2017-03-09", "https://www.nasdaq.com/articles/sucampo-scmp-beats-q4-earnings-2017-view-reaffirmed-2017-03-09", "https://www.nasdaq.com/articles/perrigo-launches-first-to-market-otc-equivalent-of-rogaine-2017-03-09", "https://www.nasdaq.com/articles/allergan-agn-and-editas-tie-up-to-treat-eye-diseases-2017-03-15", "https://www.nasdaq.com/articles/glaxosmithklines-nucala-positive-in-label-expansion-study-2017-03-07", "https://www.nasdaq.com/articles/adaptimmune-therapeutics-adap-jumps%3A-stock-rises-10.5-2017-03-06", "https://www.nasdaq.com/articles/nabriva-therapeutics-nbrv-catches-eye%3A-stock-gains-9.8-2017-03-03", "https://www.nasdaq.com/articles/incyte-treats-first-patient-in-phase-ii-gvhd-study-on-jakafi-2017-01-02", "https://www.nasdaq.com/articles/abbott-labs-to-close-st.-jude-acquisition-later-this-week-2017-01-02", "https://www.nasdaq.com/articles/immunomedics-completes-enrollment-in-cancer-drug-study-2016-12-30", "https://www.nasdaq.com/articles/cempra-cemp-gets-crl-from-fda-for-pneumonia-candidate-2016-12-30", "https://www.nasdaq.com/articles/seattle-genetics-sgen%3A-fda-lifts-hold-on-trial-of-aml-drug-2017-03-08", "https://www.nasdaq.com/articles/immunogen%3A-phase-i-data-on-ovarian-cancer-drug-published-2016-12-29", "https://www.nasdaq.com/articles/achillion-receives-%2415m-from-jj-for-hcv-study-enrolment-2016-12-29", "https://www.nasdaq.com/articles/abbott-to-sell-2-medical-device-businesses-for-st.-jude-buyout-2016-12-29", "https://www.nasdaq.com/articles/mckesson-mck-closes-rexall-health-acquisition-in-canada-2016-12-29", "https://www.nasdaq.com/articles/amphastar-stock-down-on-crl-for-asthma-drug-in-the-u.s.-2016-12-28", "https://www.nasdaq.com/articles/shire-gets-fda-approval-for-label-expansion-of-adynovate-2016-12-28", "https://www.nasdaq.com/articles/apricus-launches-vitaros-in-lebanon-for-erectile-dysfunction-2016-12-28", "https://www.nasdaq.com/articles/corbus-concludes-phase-ii-study-of-cystic-fibrosis-candidate-2016-12-30", "https://www.nasdaq.com/articles/seattle-genetics-acute-myeloid-leukemia-drug-on-fda-hold-2016-12-28", "https://www.nasdaq.com/articles/horizons-rare-disease-drug-quinsair-launched-in-canada-2016-12-27", "https://www.nasdaq.com/articles/synergy-reports-positive-top-line-phase-iii-data-on-ibs-drug-2016-12-27", "https://www.nasdaq.com/articles/ionis-biogen-spinraza-approved-for-spinal-muscular-atrophy-2016-12-27", "https://www.nasdaq.com/articles/aerie-aeri-rhopressa-regulatory-application-delayed-again-2016-12-27", "https://www.nasdaq.com/articles/celgenes-otezla-gains-positive-recommendation-from-nice-2016-12-23", "https://www.nasdaq.com/articles/roche-rhhby-hemophilia-a-drug-positive-in-phase-iii-2016-12-23", "https://www.nasdaq.com/articles/neothetics-neot-begins-phase-ii-study-on-lead-candidate-2016-12-28", "https://www.nasdaq.com/articles/seattle-genetics-acute-myeloid-leukemia-drug-on-fda-hold-2016-12-28", "https://www.nasdaq.com/articles/horizons-rare-disease-drug-quinsair-launched-in-canada-2016-12-27", "https://www.nasdaq.com/articles/synergy-reports-positive-top-line-phase-iii-data-on-ibs-drug-2016-12-27", "https://www.nasdaq.com/articles/ionis-biogen-spinraza-approved-for-spinal-muscular-atrophy-2016-12-27", "https://www.nasdaq.com/articles/aerie-aeri-rhopressa-regulatory-application-delayed-again-2016-12-27", "https://www.nasdaq.com/articles/celgenes-otezla-gains-positive-recommendation-from-nice-2016-12-23", "https://www.nasdaq.com/articles/roche-rhhby-hemophilia-a-drug-positive-in-phase-iii-2016-12-23", "https://www.nasdaq.com/articles/neothetics-neot-begins-phase-ii-study-on-lead-candidate-2016-12-28", "https://www.nasdaq.com/articles/ionis-receives-%245-million-milestone-from-jj-unit-for-gi-drug-2016-12-23", "https://www.nasdaq.com/articles/bristol-myers-calithera-team-up-for-opdivo-cb-839-combo-2016-12-22", "https://www.nasdaq.com/articles/incyte-merus-ink-collaboration-for-bispecific-antibodies-2016-12-22", "https://www.nasdaq.com/articles/exelixis-ipsen-amend-exclusive-agreement-for-cabometyx-2016-12-22", "https://www.nasdaq.com/articles/merrimack-mack-drops-as-breast-cancer-drug-trial-stops-2016-12-22", "https://www.nasdaq.com/articles/juno-gets-breakthrough-therapy-status-for-lymphoma-drug-2016-12-21", "https://www.nasdaq.com/articles/acadia-phase-ii-alzheimers-drug-hits-primary-endpoint-2016-12-21", "https://www.nasdaq.com/articles/teva-settles-foreign-bribery-charges-with-u.s.-government-2016-12-23", "https://www.nasdaq.com/articles/allergan-to-buy-lifecell-to-boost-regenerative-medicine-suite-2016-12-21", "https://www.nasdaq.com/articles/pfizer-pfe-nimenrix-vaccines-label-expanded-in-the-eu-2016-12-21", "https://www.nasdaq.com/articles/amgen-files-for-approval-of-osteoporosis-drug-in-japan-2016-12-20", "https://www.nasdaq.com/articles/abbvie-abbv-submits-nda-for-next-gen-hcv-combo-in-us-2016-12-20", "https://www.nasdaq.com/articles/sareptas-srpt-application-for-dmd-drug-accepted-in-the-eu-2016-12-20", "https://www.nasdaq.com/articles/ionis-ions-receives-milestone-payment-from-astrazeneca-2016-12-19", "https://www.nasdaq.com/articles/astrazeneca-azn-presents-tagrisso-data-at-medical-meeting-2016-12-07", "https://www.nasdaq.com/articles/juno-reports-positive-phase-i-study-data-on-lymphoma-drug-2016-12-06", "https://www.nasdaq.com/articles/abbvie-crohns-disease-drug-gets-orphan-drug-status-in-u.s.-2016-12-01", "https://www.nasdaq.com/articles/achillion-jj-to-initiate-phase-iib-study-on-hcv-combo-2016-12-01", "https://www.nasdaq.com/articles/ultragenyx-rare-reports-positive-phase-ii-study-on-ux007-2016-12-01", "https://www.nasdaq.com/articles/time-to-focus-on-heska-hska-for-strong-earnings-growth-potential-2016-11-30", "https://www.nasdaq.com/articles/valeant-vrx-ups-sales-force-to-support-xifaxan-relistor-2016-11-30", "https://www.nasdaq.com/articles/novartis-offers-positive-data-on-breast-cancer-drug-lee011-2016-12-12", "https://www.nasdaq.com/articles/amicus-provides-regulatory-update-on-fabry-disease-drug-2016-11-29", "https://www.nasdaq.com/articles/mallinckrodt-mnk-tops-q4-earnings-on-solid-sales-growth-2016-11-29", "https://www.nasdaq.com/articles/glaxo-gsk-files-regulatory-application-for-shingrix-in-eu-2016-11-28", "https://www.nasdaq.com/articles/mercks-new-drugs-cost-management-to-fuel-growth-in-2017-2016-11-25", "https://www.nasdaq.com/articles/opko-health-opk-launches-kidney-drug-rayaldee-in-u.s.-2016-11-25", "https://www.nasdaq.com/articles/junos-rocket-study-on-clinical-hold-again-shares-down-2016-11-24", "https://www.nasdaq.com/articles/is-heska-hska-stock-a-solid-choice-right-now-2016-11-23", "https://www.nasdaq.com/articles/jazz-completes-patient-enrollment-in-jzp-110-narcolepsy-trial-2016-11-29", "https://www.nasdaq.com/articles/amicus-provides-regulatory-update-on-fabry-disease-drug-2016-11-29", "https://www.nasdaq.com/articles/mallinckrodt-mnk-tops-q4-earnings-on-solid-sales-growth-2016-11-29", "https://www.nasdaq.com/articles/glaxo-gsk-files-regulatory-application-for-shingrix-in-eu-2016-11-28", "https://www.nasdaq.com/articles/mercks-new-drugs-cost-management-to-fuel-growth-in-2017-2016-11-25", "https://www.nasdaq.com/articles/opko-health-opk-launches-kidney-drug-rayaldee-in-u.s.-2016-11-25", "https://www.nasdaq.com/articles/junos-rocket-study-on-clinical-hold-again-shares-down-2016-11-24", "https://www.nasdaq.com/articles/is-heska-hska-stock-a-solid-choice-right-now-2016-11-23", "https://www.nasdaq.com/articles/jazz-completes-patient-enrollment-in-jzp-110-narcolepsy-trial-2016-11-29", "https://www.nasdaq.com/articles/agios-presents-data-from-dose-expansion-study-of-ag-120-2016-11-21", "https://www.nasdaq.com/articles/apricus-biosciences-aims-to-resubmit-vitaros-nda-in-2017-2016-11-21", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-heska-hska-time-to-buy-2016-11-17", "https://www.nasdaq.com/articles/acadia-starts-phase-ii-schizophrenia-study-on-pimavanserin-2016-11-16", "https://www.nasdaq.com/articles/lilys-jardiance-effective-in-lowering-cardiovascular-death-2016-11-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-enzo-biochem-exelixis-genmab-a-s-heska-and-incyte-2016", "https://www.nasdaq.com/articles/intrexon-xon-reports-in-line-loss-in-q3-revenues-miss-2016-11-11", "https://www.nasdaq.com/articles/allergans-fibristal-approved-in-canada-for-label-expansion-2016-11-22", "https://www.nasdaq.com/articles/agios-presents-data-from-dose-expansion-study-of-ag-120-2016-11-21", "https://www.nasdaq.com/articles/apricus-biosciences-aims-to-resubmit-vitaros-nda-in-2017-2016-11-21", "https://www.nasdaq.com/articles/earnings-estimates-moving-higher-for-heska-hska-time-to-buy-2016-11-17", "https://www.nasdaq.com/articles/acadia-starts-phase-ii-schizophrenia-study-on-pimavanserin-2016-11-16", "https://www.nasdaq.com/articles/lilys-jardiance-effective-in-lowering-cardiovascular-death-2016-11-14", "https://www.nasdaq.com/articles/the-zacks-analyst-blog-highlights%3A-enzo-biochem-exelixis-genmab-a-s-heska-and-incyte-2016", "https://www.nasdaq.com/articles/intrexon-xon-reports-in-line-loss-in-q3-revenues-miss-2016-11-11", "https://www.nasdaq.com/articles/allergans-fibristal-approved-in-canada-for-label-expansion-2016-11-22", "https://www.nasdaq.com/articles/puma-pbyi-posts-wider-loss-in-q3-neratinib-in-focus-2016-11-10", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-heska-teradyne-nxstage-medical-unifi-and-rollins-2016-11-09", "https://www.nasdaq.com/articles/heska-hska-shares-march-higher-can-it-continue-2016-11-08", "https://www.nasdaq.com/articles/no-clue-of-upcoming-trends-buy-these-efficient-stocks-2016-11-08", "https://www.nasdaq.com/articles/top-ranked-momentum-stocks-to-buy-for-november-4th-2016-11-04", "https://www.nasdaq.com/articles/myriad-genetics-to-present-myrisk-data-at-seattle-conference-2016-09-28", "https://www.nasdaq.com/articles/qiagen%3A-molecular-diagnostics-expansion-plans-on-track-2016-09-16", "https://www.nasdaq.com/articles/sucampo-scmp-beats-q3-earnings-revenues-guides-up-2016-11-10", "https://www.nasdaq.com/articles/endure-market-volatility-with-these-5-low-beta-stocks-2016-09-08", "https://www.nasdaq.com/articles/masimo-amends-nellcors-pulse-oximetry-royalty-agreement-2016-09-06", "https://www.nasdaq.com/articles/myriad-genetics-adds-assurex-health-grows-in-neuroscience-2016-09-06", "https://www.nasdaq.com/articles/illumina-keen-on-genome-network-growth-global-expansion-2016-08-26", "https://www.nasdaq.com/articles/align-technologys-invisalign-dependence%3A-boon-or-curse-2016-08-17", "https://www.nasdaq.com/articles/fda-approves-edwards-lifesciences-intuity-elite-heart-valve-2016-08-17", "https://www.nasdaq.com/articles/myriad-genetics%3A-q4-hit-by-low-test-revenues-gross-margin-2016-08-16", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-sanderson-farms-childrens-place-heska-carbonite-and", "https://www.nasdaq.com/articles/pharmerica-pmc-q2-earnings-in-line-revenues-beat-2016-08-11", "https://www.nasdaq.com/articles/heska-hska-shares-march-higher-can-it-continue-2016-08-10", "https://www.nasdaq.com/articles/biotelemetry-beat-q2-earnings-revenues-beat-view-up-2016-08-09", "https://www.nasdaq.com/articles/arenas-arna-q2-loss-narrower-revenues-increase-yy-2016-08-09", "https://www.nasdaq.com/articles/kite-pharma-kite-q2-loss-wider-focus-kte-c19-2016-08-09", "https://www.nasdaq.com/articles/strength-seen-in-heska-hska%3A-stock-jumps-5.7-in-session-2016-07-11", "https://www.nasdaq.com/articles/myriad-genetics-mychoice-cancer-test-findings-encourage-2016-07-01", "https://www.nasdaq.com/articles/mednax-md-acquires-anesthesiology-practice-in-nevada-2016-08-15", "https://www.nasdaq.com/articles/heska-hska-sees-hammer-chart-pattern%3A-time-to-buy-2016-06-15", "https://www.nasdaq.com/articles/new-strong-buy-stocks-june-2nd-2016-06-02", "https://www.nasdaq.com/articles/galena-biopharma-gale-in-focus%3A-stock-moves-up-19.3-2016-06-02", "https://www.nasdaq.com/articles/kite-pharma-kite-posts-narrower-expected-loss-q1-2016-05-10", "https://www.nasdaq.com/articles/arenas-arna-q1-loss-narrower-revenues-fall-short-2016-05-10", "https://www.nasdaq.com/articles/juno-juno-posts-wider-loss-q1-focus-pipeline-2016-05-10", "https://www.nasdaq.com/articles/new-strong-buy-stocks-for-may-5th-2016-05-05", "https://www.nasdaq.com/articles/dodge-market-volatility-with-these-5-low-beta-stocks-2016-05-17", "https://www.nasdaq.com/articles/7-rated-small-cap-stocks-line-your-pockets-2016-01-11", "https://www.nasdaq.com/articles/oncomed-omed-looks-good%3A-stock-moves-6.1-higher-2016-01-06", "https://www.nasdaq.com/articles/can-the-rally-in-heska-hska-shares-continue-2015-12-30", "https://www.nasdaq.com/articles/5-best-performing-russell-2000-stocks-of-2015-2015-12-29", "https://www.nasdaq.com/articles/heska-hska-looks-good%3A-stock-adds-5-in-session-2015-12-28", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-cal-maine-misses-q2-expectations-2015-12-24", "https://www.nasdaq.com/articles/should-you-dump-cardiovascular-systems-csii-now-2015-12-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update-stratasys-rises-upbeat-q4-results-ciena-shares-slide-2016-03", "https://www.nasdaq.com/articles/7-rated-small-cap-stocks-line-your-pockets-2016-01-11", "https://www.nasdaq.com/articles/oncomed-omed-looks-good%3A-stock-moves-6.1-higher-2016-01-06", "https://www.nasdaq.com/articles/can-the-rally-in-heska-hska-shares-continue-2015-12-30", "https://www.nasdaq.com/articles/5-best-performing-russell-2000-stocks-of-2015-2015-12-29", "https://www.nasdaq.com/articles/heska-hska-looks-good%3A-stock-adds-5-in-session-2015-12-28", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-cal-maine-misses-q2-expectations-2015-12-24", "https://www.nasdaq.com/articles/should-you-dump-cardiovascular-systems-csii-now-2015-12-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update-stratasys-rises-upbeat-q4-results-ciena-shares-slide-2016-03", "https://www.nasdaq.com/articles/7-rated-small-cap-stocks-line-your-pockets-2016-01-11", "https://www.nasdaq.com/articles/oncomed-omed-looks-good%3A-stock-moves-6.1-higher-2016-01-06", "https://www.nasdaq.com/articles/can-the-rally-in-heska-hska-shares-continue-2015-12-30", "https://www.nasdaq.com/articles/5-best-performing-russell-2000-stocks-of-2015-2015-12-29", "https://www.nasdaq.com/articles/heska-hska-looks-good%3A-stock-adds-5-in-session-2015-12-28", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-cal-maine-misses-q2-expectations-2015-12-24", "https://www.nasdaq.com/articles/should-you-dump-cardiovascular-systems-csii-now-2015-12-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update-stratasys-rises-upbeat-q4-results-ciena-shares-slide-2016-03", "https://www.nasdaq.com/articles/7-rated-small-cap-stocks-line-your-pockets-2016-01-11", "https://www.nasdaq.com/articles/oncomed-omed-looks-good%3A-stock-moves-6.1-higher-2016-01-06", "https://www.nasdaq.com/articles/can-the-rally-in-heska-hska-shares-continue-2015-12-30", "https://www.nasdaq.com/articles/5-best-performing-russell-2000-stocks-of-2015-2015-12-29", "https://www.nasdaq.com/articles/heska-hska-looks-good%3A-stock-adds-5-in-session-2015-12-28", "https://www.nasdaq.com/articles/mid-morning-market-update-markets-edge-lower-cal-maine-misses-q2-expectations-2015-12-24", "https://www.nasdaq.com/articles/should-you-dump-cardiovascular-systems-csii-now-2015-12-23", "https://www.nasdaq.com/articles/mid-afternoon-market-update-stratasys-rises-upbeat-q4-results-ciena-shares-slide-2016-03", "https://www.nasdaq.com/articles/should-heska-corporation-hska-be-on-your-radar-now-2015-12-11", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-vnda-jumps%3A-stock-rises-7.9-2015-12-10", "https://www.nasdaq.com/articles/should-you-retain-integra-lifesciences-iart-in-your-portfolio-2015-12-09", "https://www.nasdaq.com/articles/bluebird-bio-crashes-after-clinical-trial-update-2015-12-07", "https://www.nasdaq.com/articles/should-you-dump-illumina-ilmn-from-your-portfolio-now-2015-12-07", "https://www.nasdaq.com/articles/repros-therapeutics-rprx-looks-good%3A-stock-soars-45.1-2015-11-30", "https://www.nasdaq.com/articles/can-heska-hska-stock-continue-to-grow-earnings-2015-11-18", "https://www.nasdaq.com/articles/myriad-genetics%3A-test-expansion-strong-currency-woes-linger-2015-12-22", "https://www.nasdaq.com/articles/strength-seen-in-heska-hska%3A-stock-moves-11.5-higher-2015-11-12", "https://www.nasdaq.com/articles/will-heska-hska-continue-to-surge-higher-tale-of-the-tape-2015-08-05", "https://www.nasdaq.com/articles/why-heska-corporation-hska-could-be-an-impressive-growth-stock-tale-of-the-tape-2015-08-04", "https://www.nasdaq.com/articles/integra-tops-earnings-revenues-guides-low-on-spine-sale-analyst-blog-2015-08-03", "https://www.nasdaq.com/articles/qiagen-qgen-beats-q2-earnings-revenues-keeps-15-view-analyst-blog-2015-07-31", "https://www.nasdaq.com/articles/repros-therapeutics-rprx-worth-watching%3A-stock-up-17-tale-of-the-tape-2014-09-29", "https://www.nasdaq.com/articles/rexahn-pharmaceuticals-rnn-jumps%3A-stock-gains-10.2-tale-of-the-tape-2014-09-26", "https://www.nasdaq.com/articles/can-the-uptrend-continue-for-heska-hska-tale-of-the-tape-2014-12-26", "https://www.nasdaq.com/articles/qiagens-molecular-diagnostics-global-market-show-strength-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/dynavax-dvax-jumps%3A-stock-moves-6.7-higher-tale-of-the-tape-2014-09-22", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-aldr-in-focus%3A-stock-up-5.2-tale-of-the-tape-2014-09-18", "https://www.nasdaq.com/articles/dendreon-dndn-in-focus%3A-stock-up-9.4-tale-of-the-tape-2014-09-16", "https://www.nasdaq.com/articles/is-illumina-ilmn-a-buy-on-solid-q2-strategic-road-map-analyst-blog-2014-09-16", "https://www.nasdaq.com/articles/cytokinetics-cytk-looks-strong%3A-stock-gains-17.2-tale-of-the-tape-2014-09-11", "https://www.nasdaq.com/articles/discovery-laboratories-dsco-worth-watching%3A-stock-up-6.9-tale-of-the-tape-2014-08-21", "https://www.nasdaq.com/articles/myriad-genetics-poised-on-strong-myrisk-overseas-results-analyst-blog-2014-09-26", "https://www.nasdaq.com/articles/genomic-health-remains-neutral-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/synthetic-biologics-syn-in-focus%3A-stock-surges-18.1-tale-of-the-tape-2013-12-24", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-catches-eyes%3A-stock-jumps-8.6-tale-of-the-tape-2013-12-24", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-plc-jazz-catches-eye%3A-stock-rises-8-tale-of-the-tape-2013-12-23", "https://www.nasdaq.com/articles/myriad-maintained-at-neutral-analyst-blog-2013-12-23", "https://www.nasdaq.com/articles/affymetrix-reaches-new-52-week-high-analyst-blog-2013-12-23", "https://www.nasdaq.com/articles/ariad-pharmaceuticals-aria-worth-watching%3A-stock-surges-19.7-tale-of-the-tape-2013-12-19", "https://www.nasdaq.com/articles/edwards-lifesciences-lifted-to-hold-analyst-blog-2013-12-31", "https://www.nasdaq.com/articles/mygn-announces-results-of-hrd-test-analyst-blog-2013-12-17", "https://www.nasdaq.com/articles/iart-publishes-positive-study-results-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/mygn-unveils-positive-study-results-analyst-blog-2013-12-13", "https://www.nasdaq.com/articles/davita-healthcare-partners-dva-catches-eye%3A-stock-rises-6.7-tale-of-the-tape-2013-12-10", "https://www.nasdaq.com/articles/verastem-vstm-in-focus%3A-stock-rises-by-7.3-tale-of-the-tape-2013-12-06", "https://www.nasdaq.com/articles/mygn-unveils-prolaris-study-results-analyst-blog-2013-12-05", "https://www.nasdaq.com/articles/sangamo-biosciences-sgmo-in-focus%3A-stock-rises-5.8-tale-of-the-tape-2013-12-04", "https://www.nasdaq.com/articles/agenus-agen-soars%3A-stock-adds-12.7-in-session-tale-of-the-tape-2013-12-17", "https://www.nasdaq.com/articles/mygn-announces-results-of-hrd-test-analyst-blog-2013-12-17", "https://www.nasdaq.com/articles/iart-publishes-positive-study-results-analyst-blog-2013-12-16", "https://www.nasdaq.com/articles/mygn-unveils-positive-study-results-analyst-blog-2013-12-13", "https://www.nasdaq.com/articles/oncothyreon-inc.-onty-in-focus%3A-stock-up-5.2-tale-of-the-tape-2013-12-02", "https://www.nasdaq.com/articles/transition-therapeutics-tthi-jumps%3A-stock-adds-7.0-in-session-tale-of-the-tape-2013-11-27", "https://www.nasdaq.com/articles/chelsea-therapeutics-chtp-looks-good%3A-stock-moves-8.9-higher-tale-of-the-tape-2013-11-27", "https://www.nasdaq.com/articles/affymetrix-remains-outperform-analyst-blog-2013-12-04", "https://www.nasdaq.com/articles/athersys-athx-catches-eye%3A-stock-jumps-5.5-tale-of-the-tape-2013-11-26", "https://www.nasdaq.com/articles/curis-inc.-cris-soars%3A-stock-adds-11.7-in-session-tale-of-the-tape-2013-11-26", "https://www.nasdaq.com/articles/davita-healthcare-partners-dva-shows-strength%3A-stock-rises-8.9-tale-of-the-tape-2013-11-26", "https://www.nasdaq.com/articles/ghdx-partners-almac-for-cancer-test-analyst-blog-2013-11-26", "https://www.nasdaq.com/articles/dynavax-technologies-dvax-catches-eye%3A-stock-rises-5.2-tale-of-the-tape-2013-11-25", "https://www.nasdaq.com/articles/vanda-pharmaceuticals-inc.-vnda-grabs-attention%3A-stock-shoots-95.9-tale-of-the-tape-2013", "https://www.nasdaq.com/articles/arena-pharmaceuticals-arna-worth-a-look%3A-stock-surges-10.6-tale-of-the-tape-2013-11-12", "https://www.nasdaq.com/articles/athersys-athx-jumps%3A-stock-rises-by-9.2-tale-of-the-tape-2013-11-22"], "Content": []}